Detalle Publicación

Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

Autores: Caballero-Marcos, A.; Salcedo, M. (Autor de correspondencia); Alonso-Fernández, R.; Rodríguez-Perálvarez, M.; Olmedo, M.; Morales, J. G.; Cuervas-Mons, V.; Cachero, A.; Loinaz-Segurola, C.; Iñarrairaegui Bastarrica, Mercedes; Castells, L.; Pascual, S.; Vinaixa-Aunés, C.; González-Grande, R.; Otero, A.; Tomé, S.; Tejedor-Tejada, J.; Álamo-Martínez, J. M.; González-Diéguez, L.; Nogueras-López, F.; Blanco-Fernández, G.; Muñoz-Bartolo, G.; Bustamante, F. J.; Fábrega, E.; Romero-Cristóbal, M.; Martín-Mateos, R.; Del-Río-Izquierdo, J.; Arias-Milla, A.; Calatayud, L.; Marcacuzco-Quinto, A. A.; Fernández-Alonso, V.; Gómez-Gavara, C.; Colmenero, J.; Muñoz, P.; Pons, J. A.; Spanish Society of Liver Transplantation (SETH)
Título de la revista: AMERICAN JOURNAL OF TRANSPLANTATION
ISSN: 1600-6135
Volumen: 21
Número: 8
Páginas: 2876 - 2884
Fecha de publicación: 2021
Resumen:
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17-83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03-1.36), and therapy with renin-angiotensin-aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47-34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline.